Loading…
Loading…
Nov Inc. (NOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NOV's technology gains, rising earnings estimates, strong backlog and shareholder returns strengthen its long-term outlook despite trailing some peers.
NOV provides a conservative balance sheet with a current ratio of roughly 2.4x and low debt levels. SLB N.V. leverages a massive global footprint to generate substantial free cash flow nearing $4.8 billion.
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn's Disease (FSCD). Approximately 46% of Crohn's disease patients have FSCD, or fibrotic strictures in the intestinal tract, which can cause obstructive symptoms leading to dietary change, malnutrition and surgery.
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) will hold a conference call to discuss its second quarter 2026 results on Wednesday, July 29, 2026, at 10 a.m. (Central Time).
NOV shares rise 32% over the past six months as offshore demand, backlog growth and efficiency gains boost prospects despite tariffs and risks.
Nov Inc. (NOV) reported earnings 30 days ago. What's next for the stock?
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.09 per share of common stock, payable on June 26, 2026 to each stockholder of record on June 12, 2026.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for NOV and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.